scispace - formally typeset
Journal ArticleDOI

Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial

Reads0
Chats0
TLDR
The OPTIMA trial, which has just opened to recruitment in the UK, is the latest addition to trials in this area, and is the first to focus on the relative cost-effectiveness of alternate predictive assays.
About
This article is published in Clinical Oncology.The article was published on 2013-02-01. It has received 46 citations till now. The article focuses on the topics: Breast cancer.

read more

Citations
More filters
Journal ArticleDOI

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

TL;DR: In this article, a prospective trial involving women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0cm in the intermediate or high tumor grade) who met established guidelines for the consideration of adjuvant chemotherapy on the basis of clinicopathologic features.
Journal ArticleDOI

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others

TL;DR: Existing evidence on the comparative prognostic information provided by different tests suggests that current multiparameter tests provide broadly equivalent risk information for the population of women with estrogen receptor (ER)-positive breast cancers, however, for the individual patient, tests may provide differing risk categorization and subtype information.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

TL;DR: Among patients with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who met established guidelines for the recommendation of adjuvant chemotherapy on the basis of clinicopathologic features, those with tumors that had a favorable gene-expression profile had very low rates of recurrence at 5 years with endocrine therapy alone.
Journal ArticleDOI

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis

TL;DR: There is limited and varying evidence that oncotype DX and MammaPrint can predict benefit from chemotherapy, but the review suggests that all the tests can provide prognostic information on the risk of relapse.
References
More filters
Journal ArticleDOI

Molecular portraits of human breast tumours

TL;DR: Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.
Journal ArticleDOI

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

TL;DR: Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.
Journal ArticleDOI

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

TL;DR: The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients.
Related Papers (5)

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

O. Abe, +412 more
- 14 May 2005 -